Introduction
The antiphospholipid syndrome (APS) was defined by Harris et al. in 1986 as a condition with recurrent venous/arterial thrombosis and/or preg-ously; whereas, secondary APS refers to patients with an underlying autoimmune condition. In a recent study of pediatric APS, 49.5% of 121 patients had an underlying autoimmune disease which was predominantly systemic lupus erythematous (SLE) [2] . In 1992, Asherson described "the catastrophic" antiphospholipid syndrome (CAPS) as a rare variant of APS, occurring in less than 1% of cases, associated with multiple small vessel thromboses resulting in multi-organ failure with high mortality [3] . The validated diagnostic criteria of definite CAPS includes: 1) involvement of three or more organ systems, 2) development of manifestations in less than one week, 3) histopathologic confirmation of small vessel occlusion in at least one organ/tissue, and 4) the presence of aPL [4] [5] . CAPS is triggered most commonly by infection, but also by surgery, pregnancy, malignancy, and SLE flares [6] . The clinical overlap with the thrombotic microangiopathic syndromes, disseminated intravascular coagulopathy (DIC) and sepsis makes the diagnosis of CAPS challenging in intensive care settings [7] [8] . CAPS is also characterized by a systemic inflammatory response in which massive cytokine release triggers acute respiratory distress syndrome (ARDS), cerebral edema and myocardial dysfunction [9] . Early diagnosis is crucial since treatment with anticoagulation, steroids, plasma exchange and other immune modulators such as rituximab has been shown to improve outcomes [10] . We present the case of a 5 year old female with primary CAPS associated with multi-organ failure and review a series of pediatric cases reported as case reports or case series in the literature over the last 23 years.
Methods With an index case identified, a literature review of published cases of CAPS was undertaken and included the current electronic databases of Medline, PubMed and Google Scholar. The search included pediatric cases between the ages of 0-18 years who met classification criteria for definite or probable CAPS [4] . The year for initiation of the search was set after 1992 when the first 10 patients with CAPS were reported [3] . Two patients in that series were <15 years of age.
Basic statistical analyses were used to obtain the population mean and standard deviation. The odds ratios for treatment efficacy were determined by Fisher' s exact test in analysis of contingency tables.
This report includes a single index case from Holtz Children' s Hospital. In compliance with the Health Insurance Portability and Accountability Act (HIPAA) and consistent with ethical standards currently applied in the USA, no personally identifiable data were used.
Case Report A 5 year old female was transferred with acute liver failure, respiratory distress and severe metabolic acidosis. Her past medical history was notable for two episodes of febrile seizures. She was healthy except for a week of dry cough until the day prior to presentation when she developed fever, abdominal pain, vomiting, non-bloody diarrhea and lethargy. She presented to a local emergency room where she was febrile, tachycardic and tachypneic. Worsening respiratory status, coagulopathy and hypotension prompted transfer to our pediatric intensive care unit for further management and consideration for liver transplantation.
On arrival, she remained febrile, tachycardic, and tachypneic with hypotension. Her examination was notable for hepatomegaly. Chest x-ray showed pulmonary edema and bilateral pleural effusions ( Figure 1A ). Laboratory evaluation revealed lactic acidosis, acute kidney injury, transaminitis, worsening coagulopathy, leucopenia and microangiopathic hemolytic anemia with thrombocytopenia (Table 1) . She required multiple rounds of plasma, cryoprecipitate, platelets and blood products. Her respiratory and mental status worsened, prompting intubation. A pulseless bradycardic event occurred. Administration of epinephrine, atropine and chest compressions reestablished sinus rhythm and perfusion. She developed ARDS and was switched to high frequency oscillatory ventilation ( Figure 1B) . She had refractory hypotension requiring pressor support. Continuous renal replacement therapy (CRRT) was initiated on hospital day 1 for oliguric renal failure. She underwent a bedside exploratory laparotomy with silo placement for abdominal compartment syndrome. Serratia marcescens was recovered from a blood culture and metapneumovirus grew from an endotracheal culture. Broad spectrum antibiotic coverage with piperacillin-tazobactam, meropenem, vancomycin and acyclovir was consolidated to meropenem for 14 days. Plasma exchange was initiated on hospital day 2 for thrombocytopenia associated multi-organ system failure (TAMOF) [11] . Initial diagnostic evaluation for causes of the microangiopathy was initially inconclusive (Table 1) . Her ADAMTS-13 activity was low 32% (56-253% reference range). There were no large vessel thrombosis clinically suspected and a duplex abdominal ultrasound was negative for thrombosis.
Following 3 consecutive daily sessions of plasma exchange, her clinical status improved with decreased pressor and ventilatory support. Her liver and metabolic dysfunction also began improving (Table 1) . Liver biopsy on day 6 demonstrated evidence of acute hepatitis, mild to moderate fibrosis Figure 2 . Antiphospholipid antibody levels: Multimodal therapy resulted in normalization of anticardiolipin IgG Ab after 9 months (normal <12 U/ml) (A); anticardiolipin IgA normalized after 6 weeks (normal <10 U/ml) (B); anticardiolipin IgM was not elevated (normal <10 U/ ml) (B); β2 glycoprotein IgG Ab improved but still elevated 9 months (normal <20 SGU) and β2 glycoprotein IgM as not elevated (normal <20 SGU) (C). (Note: β2 glycoprotein assay upper limit of detection =150 SGU). Key: TMA-thrombotic microangiopathy, PCS-pulse corticosteroids, ASA-aspirin, PE-plasma exchange/pheresis, CTX-cyclophosphamide, CSA-cyclosporine, RTX-Rituximab, AZA-azathioprine, MMF-mycophenolate mofetil, AC= anticoagulation (heparin, low molecular weight heparin and/or warfarin), APS-antiphospholipid syndrome, SLE-systemic lupus erythematousus, LAC-lupus anticoagulant, aPL-antiphospholipid antibodies, aCL-anticardiolipin antibodies, anti-β2GP-1 -anti-β2 glycoprotein-1 antibody, aPS/PT Ab-anti-phosphatidylserine-prothrombin antibody; IVC-inferior vena cava, SVC-superior vena cava, IVIG-intravenous immunoglobulin.
Days
with microthrombi in the portal vein. CRRT was discontinued on day 7 and 3 sessions of acute intermittent hemodialysis were performed over the subsequent week. She was tracheally extubated by day 8. She developed hypertension and was started on amlodipine and labetalol.
On hospital day 17, aPL were sent and results showed marked elevation of several antibodies especially anticardiolipin and the lupus anticoagulant was negative (Figure 2 ). Upon tapering of stress dose steroids, she developed fever, a pleural effusion, worsening anemia and aggravated inflammatory markers. This change was attributed to untreated CAPS. Hence, she was treated with methylprednisolone 15mg/kg for 3 daily doses. Her fevers subsided and respiratory status stabilized. Prednisone was weaned slowly to 10mg daily (0.5mg/ kg) which she continued on discharge.
On hospital day 25, with persistent depressed renal function (Cystatin C =1.1mg/L; normal <0.8mg/L) and significant proteinuria (protein to creatinine ratio 1.66; microalbumin to creatinine ratio 635mcg/mg) a renal biopsy was obtained. The biopsy yielded 5 glomeruli and showed foci of moderate acute tubular epithelial cell injury without evidence of microangiopathy or thrombosis. She was started on enoxaparin injections for prevention of thrombosis. On day 30, she received rituximab 375mg/m2. Low dose angiotensin receptor blockade was started for mild hypertension and renoprotection. She was discharged after 32 days of hospitalization.
The patient returned in 1-2 week intervals for 3 additional doses of rituximab to complete a cumulative dose of 1.5g/m2. Her renal function normalized (Cystatin C= 0.52) and pro-teinuria improved (total protein to creatinine ratio 0.4; microalbumin to creatinine ratio 10.5mcg/mg). Her aPL were followed and showed steady improvement with normalization of aCL IgG and IgA. The anti-β2GP-1 IgG remains elevated at low titers (Figure 2 ). One year after initial presentation she is stable on low dose aspirin and angiotensin converting enzyme inhibition.
Results Twenty-one patients were identified: our index case and 20 from the literature since 1990. Clinical and laboratory characteristics of each of the cases are shown in Table 2 . The age range was 3 months to 18 years (mean 10.5 ± 4.8 years; median=12 years). Fourteen (66%) were female. The majority (76%) had primary onset without evidence of autoimmune disease; whereas, 5 (24%) were secondary to systemic lupus erythematosus (SLE). There was an infectious trigger in 13 (62%), 2 followed surgery; 3 were secondary to SLE exacerbation without infection; 1 had CAPS as the primary manifestation of a malignancy and 2 had no known trigger.
There were 5 deaths. Most patients were treated with immunosuppressive regimens [17] including pulse corticosteroids [16] , plasma exchange [8] , cyclophosphamide [5] and/ or rituximab [4] . Other adjuvant therapies included intravenous gamma globulin (IVIG) [9] and anticoagulation [17] . Although the number of patients was too small to reach statistical significance, the odds ratios (OR) for survival were calculated for the various treatment regimens ( tients who received immune suppression were 4 times more likely to survive than those who did not. Pulse corticosteroids offered an odds ratio of 9 for survival when included in the immunosuppressive regimen. Although only 4 patients received rituximab as a component of therapy, none died, giving them an odds ratio of 4.7 for survival. Plasma exchange, cyclophosphamide and anticoagulation therapy provided no advantage for survival; whereas, IVIG administration was associated with higher mortality. Discussion In this case report and review of the literature, we demonstrate the benefit of early recognition and treatment of primary CAPS in pediatric patients. The diagnosis of definite CAPS in our patient was reached with evidence of multi-organ failure within one week of an infectious trigger, thrombotic microangiopathy on liver biopsy, and significantly elevated aPL. Despite having acute kidney injury requiring CRRT, the kidney biopsy, unlike the liver biopsy, did not show evidence of microangiopathy. This may reflect recovery of kidney injury since the biopsy was performed 25 days after treatment initiation. Sampling error, with only 5 glomeruli included, could also be a factor. There are scarce data on histopathological features in CAPS patients. However, a small series of 6 adult patients uniformly showed microangiopathic lesions in the kidney and many showed "chronic changes" including tubular atrophy, fibrous intimal hyperplasia and focal cortical atrophy [12] .
Given the rarity of the condition, much of the literature on pediatric CAPS is in the form of case reports or small case series ( Table 2 ). The youngest cases reported have been of a 3 month old and a 2 and 3 year old [6, [13] [14] [15] . Hence, we report one of the youngest published cases of CAPS to date. A recent review of the CAPS registry reported 45 pediatric cases of CAPS among 121 total pediatric patients with APS. The review compares pediatric versus adult CAPS in the registry and concludes that pediatric CAPS patients are more likely than adults to have an infection trigger CAPS and to have the catastrophic APS be the first manifestation of APS, both of which were true in our case [16] . Renal involvement is one of the most frequent manifestations of CAPS, as was also true in our case [17] . In addition, our patient also had DIC and ARDS which have been reported in CAPS patients with frequencies of 13% and 21%, respectively [8, 18] . Treatment of CAPS has included multimodal therapy with plasma exchange, anticoagulation and immune modulators [19] . In a recent review of 250 patients in the CAPS registry, 44.8% of patients died during a 5 year period with the highest recovery rate (78%) seen in those who received a combination of anticoagulation, corticosteroids and plasma exchange [20] . We initiated plasma exchange early because the patient met criteria for TAMOF before results of aPL were available [11] . Rituximab has been used with success in adults with resistant primary APS and refractory APS [21] [22] . In 2007, a literature review noted uniformly positive results in 13 cases of primary and secondary CAPS treated with rituximab. Most cases were treated with a 375mg/m2 for four weekly doses, which is how we treated our patient [23] . In addition, recent case reports of probable pediatric CAPS describe success with rituximab treatment [15, [23] [24] . Of note, rituximab was not used in any of the 45 pediatric CAPS cases recently reviewed from the CAPS registry. Hence, it is unknown what affect if any rituximab would have added to the survival benefit of multimodal therapy in this large group of patients [16] . In the current report the number of patients reviewed is too small to draw conclusions. However, the odds ratios for survival offer support for the early use of immune modulation including pulse corticosteroids and rituximab. Similar findings of a potential benefit of Rituximab use especially in cases of refractory CAPS in adults were recently reported from the CAPS registry [25] .
Nearly half of patients with APS and CAPS have an underlying autoimmune disease, most often SLE [6] . In addition, in pediatric APS, up to 30% of patients (15/50) initially diagnosed with primary APS, later developed SLE [2] . This is more than 4 times higher than in adults [25] . In adults, important distinctions have been made between CAPS patients, with and without SLE. Patients with SLE CAPS are more often female, younger and have higher mortality [26] . Hence, it is important that CAPS patients are followed by a rheumatologist for continued screening even if SLE is not diagnosed initially.
Long term hematologic surveillance is also important since episodes of recurrent thrombosis in both APS and CAPS have been observed [27] [28] . Overall, 23 (19%) of 121 pediatric APS patients developed further APS-related thrombosis after the initial thrombotic event [2] . Furthermore, data on the presence of inherited prothrombotic disorders revealed at least one hereditary thrombophilic risk factor in 45% of these patients [2] .
In conclusion, we have reported one of the youngest cases of CAPS published to date and reviewed the literature of pediatric CAPS. Although more is being reported through the international web based registry, pediatric CAPS is still not well understood and definitive treatment regimens are not well established. This case, along with previously published reports, highlights the need for a heightened awareness of the condition in children. Clinicians should consider screening patients for aPL in cases of multi-organ failure, especially if known to have an autoimmune disorder, to allow for prompt diagnosis and early treatment. Multimodal therapy with anticoagulation and immunomodulatory agents such as Rituximab should be considered since there seems to be a tendency towards increased survival.
Key Messages: • CAPS should be considered in the differential diagnosis of acute onset multi-organ failure in pediatrics.
• Early recognition and multimodal treatment can be lifesaving including plasma exchange, immune modulation such as rituximab and chronic anticoagulation.
• CAPS requires long term rheumatologic surveillance for recurrence and potential evolution to SLE.
